Background and Objectives: EUS-guided tissue acquisition (EUS-TA) is the preferred method to acquire pancreatic cancer (PC) tissues. The factors associated with false-negative outcomes and inadequate samples should be explored to gain an understanding of EUS-TA. Methods: The patients who underwent EUS-TA for suspected solid PC but whose results were false-negative were analyzed. The PC patients who underwent EUS-TA with true-positive results on the first day of every month during the study period were selected as the control group. The factors influencing diagnostic accuracy and sample adequacy were explored. Results: From November 2017 to January 2022, 184 patients were included in the false-negative group, and 175 patients were included in the control group. Multivariate logistic regression demonstrated that the recent acute pancreatitis [odds ratio (OR): 0.478, 95% confidence interval (CI): 0.250–0.914, P = 0.026] and high echo component within the tumor (OR: 0.103, 95% CI: 0.027–0.400, P = 0.001) were independently associated with false-negative EUS-TA results. Meanwhile, using fine-needle biopsy (FNB) needles (OR: 2.270, 95% CI: 1.277–4.035, P = 0.005), more needle passes (OR: 1.651,95% CI: 1.239–2.199, P = 0.005), large tumor size (OR: 1.053, 95% CI: 1.029–1.077, P < 0.001), and high CA-19-9 level (OR: 1.001, 95% CI: 1.000–1.001, P = 0.019) were independently associated with true-positive EUS-TA outcomes. Three needle passes are needed to achieve optimal EUS-TA outcomes. Tumor location in the body/tail (OR: 1.38, 95% CI: 1.01–1.72; P = 0.04), needle passes ≥3 (OR: 1.90; 95% CI: 1.22–2.56; P < 0.001), and using the FNB needle (OR: 2.10; 95%: 1.48–2.85; P < 0.001) were independently related to sample adequacy. Conclusion: Numerous factors were identified to be associated with the diagnostic accuracy and sample adequacy of EUS-TA.
Pancreatic cystic lesions (PCLs) are a globally prevalent condition, with incidence increasing with age. The proper treatment modality for PCLs remains a controversial topic. EUS-guided ablation represents an innovative and promising minimally invasive treatment for selected PCL patients, including EUS-guided pancreatic cyst chemoablation (EUS-PCC, such as ethanol, lauromacrogol, chemotherapeutic agents, and combination therapies) and EUS-guided radiofrequency ablation (EUS-RFA). Each treatment modality varies in treatment indications, efficacy, and safety. Herein, with ongoing advancements in clinical research, we present a comprehensive, updated review of procedural techniques, patient selection, clinical outcomes, and adverse events for EUS-PCC and EUS-RFA.
Chronic pancreatitis is a progressive inflammatory disease, whose hallmark pathological feature is an irreversible fibrosis process. This process further leads to irreversible structural damage, pancreatic functional decline, and a variety of severe complications. Common complications mainly include pancreatic exocrine insufficiency, endocrine insufficiency, metabolic bone disease, pain, pancreatic duct stones, obstruction of common bile duct and duodenum, pancreatic pseudocysts, and vascular complications. This review systematically sorts out and integrates the etiology, diagnostic criteria, and management of various complications. Moreover, active intervention for these complications through secondary prevention and standardized management is crucial for improving patients’ clinical prognosis. Ultimately, this review establishes a comprehensive “Etiology-Diagnosis- Management “clinical reference system for the primary complications of chronic pancreatitis, providing gastroenterologists with a quick reference for the standardized diagnosis and management of chronic pancreatitis-related complications.
The calcium-sensing receptor, or CaSR, is a class C G protein-coupled receptor that plays a central role in systemic calcium homeostasis and exerts cell-type-specific functions in the pancreas. This review summarizes the structure, ligand recognition, and downstream signaling of CaSR, with particular emphasis on the concept that pancreatic CaSR output is determined by context-dependent signal routing rather than receptor activation alone. In acinar and ductal cells, CaSR may regulate Ca2+ signaling thresholds, bicarbonate-rich fluid secretion, luminal calcium clearance, and susceptibility to pancreatitis. In endocrine β-cells, CaSR modulates insulin secretion in a ligand- and metabolic-state-dependent manner. In pancreatic inflammation, recent single-cell studies further highlight the importance of immune-cell heterogeneity, neutrophil reactive oxygen species programs, and fibrosis-associated stromal axes. In pancreatic cancer, the apparently opposing tumor-suppressive and tumor-adaptive roles of CaSR may be reconciled by differences in tumor differentiation, extracellular calcium milieu, stromal interaction, metabolic state, and downstream effector coupling. We propose that CaSR integrates ionic, inflammatory, metabolic, and microenvironmental cues to generate distinct pancreatic outputs. This framework supports CaSR as a mechanistically informative but highly context-dependent therapeutic target.